2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Osteochondroma
1
Exostoses, Multiple Hereditary
1
Interventions
Cyclophosphamide
391
Carboplatin
344
Gemcitabine
332
pembrolizumab
331
Cisplatin
328
Paclitaxel
298
Radiotherapy
297
Docetaxel
287
Bevacizumab
253
Rituximab
234
Capecitabine
224
Nivolumab
222
Dexamethasone
206
Fluorouracil
190
fludarabine
178
Oxaliplatin
177
Pemetrexed
153
Doxorubicin
153
Irinotecan
148
Leucovorin
144
Etoposide
144
Cytarabine
134
Cetuximab
130
fludarabine phosphate
129
Bortezomib
129
Lenalidomide
126
Filgrastim
120
Erlotinib Hydrochloride
120
Temozolomide
113
Radiosurgery
113
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Palovarotene
×
Clear all
NCT03442985
2022-08-01
MO-Ped
Ipsen
Phase 2
Terminated
193 enrolled
20 charts